1. Home
  2. QCRH vs STOK Comparison

QCRH vs STOK Comparison

Compare QCRH & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo QCR Holdings Inc.

QCRH

QCR Holdings Inc.

N/A

Current Price

$99.26

Market Cap

1.7B

Sector

Finance

ML Signal

N/A

Logo Stoke Therapeutics Inc.

STOK

Stoke Therapeutics Inc.

N/A

Current Price

$26.01

Market Cap

2.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
QCRH
STOK
Founded
1993
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
2.0B
IPO Year
1996
2019

Fundamental Metrics

Financial Performance
Metric
QCRH
STOK
Price
$99.26
$26.01
Analyst Decision
Buy
Strong Buy
Analyst Count
6
14
Target Price
★ $110.50
$46.46
AVG Volume (30 Days)
63.8K
★ 638.1K
Earning Date
10-20-2026
11-03-2026
Dividend Yield
★ 0.41%
N/A
EPS Growth
11.62
★ 92.73
EPS
★ 4.18
N/A
Revenue
$165,999,610.00
★ $184,420,000.00
Revenue This Year
$4.29
N/A
Revenue Next Year
$5.50
$39.98
P/E Ratio
$23.64
★ N/A
Revenue Growth
20.72
★ 404.50
52 Week Low
$66.71
$20.32
52 Week High
$108.11
$40.22

Technical Indicators

Market Signals
Indicator
QCRH
STOK
Relative Strength Index (RSI) 33.30 38.05
Support Level $93.70 $25.21
Resistance Level $99.87 $33.92
Average True Range (ATR) 1.75 1.15
MACD -0.37 -0.17
Stochastic Oscillator 3.35 36.31

Price Performance

Historical Comparison
QCRH
STOK

About QCRH QCR Holdings Inc.

QCR Holdings Inc is a multi-bank holding company. The bank operates through segments namely Commercial Banking, Wealth Management, and all other segments. The commercial bank segment is geographically divided by markets namely Quad City Bank & Trust (QCBT), Cedar Rapids Bank & Trust (CRBT), Community State Bank (CSB) and Guaranty Bank (GB). It generates revenue in the form of interest.

About STOK Stoke Therapeutics Inc.

Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

Share on Social Networks: